The efficacy of intravitreal injection of tissue plasminogen activator, ranibizumab and C3F8 in the treatment of early submacular hemorrhage induce to polypoid choroid vasculopathy
Shuang Zhang, Jie Zhang, Xinyan Xu, Rongyu Gao, Peng Wu, Haitao Han, Xianyong Sun, Xudong Huang
Published 2018-09-25
Cite as Chin J Ocul Fundus Dis, 2018, 34(5): 448-452. DOI: 10.3760/cma.j.issn.1005-1015.2018.05.007
Abstract
ObjectiveTo observe the clinical effect of intravitreal injection of tissue plasminogen activator (t-PA), ranibizumab and C3F8 in the treatment of early submacular hemorrhage (SMH) induce to polypoid choroidal vasculopathy (PCV).
MethodsThe clinical data of 20 eyes of 20 patients with early SMH induce to PCV were enrolled in this study. The duration of bleeding in the eye was 7 to 28 days, and the mean duration of bleeding was 14.8±5.6 days. All eyes are measured using the Snellen chart best corrected visual acuity (BCVA), logarithm of the minimum angle of resolution (logMAR) was used to calculate visual acuity. Measure central retinal thickness (CRT) and central retinal pigment epithelial detachment (PED) thickness using frequency-domain optical coherence tomography. The average logMAR BCVA of eyes was 1.73±0.91; the mean CRT was 620.0±275.8 μm; the average central PED thickness was 720.3±261.9 μm. All eyes receive intravitreal injection of t-PA, ranibizumab and C3F8. The intravitreal injection of ranibizumab was administered once a month for 3 consecutive months, followed by an on-demand treatment plan. Mean follow-up time was 9.9±3.6 months. The changes in BCVA, CRT, central PED thickness and clearance degree of SMH at 6 months after treatment were observed.
ResultsOn the 6 months after treatment, the average logMAR BCVA, CRT and central PED thickness of the eyes were respectively 0.42±0.37, 290.2±97.4 μm and 41.6±78.1 μm. Compared with baseline, the after treatment BCVA was significantly increased (F=38.14, P=0.000), but the CRT and central PED were significantly decreased (F=7.48, 75.94; P=0.000, 0.000). Among the 20 eyes, 16 eyes of SMH was completely cleared, accounting for 80%;4 eyes was partially cleared, accounting for 20%. No recurrence and systemic or local complications occurred during follow-up of all eyes.
ConclusionIntravitreal injection of t- PA, ranibizumab, and C3F8 in the treatment of early SMH induce to PCV can effectively remove SMH, improve vision, reduce CRT and central thickness of PED.
Key words:
Choroid diseases/therapy; Submacular hemorrhage; Tissue plasminogen activator/therapeutic use; Angiogenesis inhibitors/therapeutic use; Noble gases/therapeutic use
Contributor Information
Shuang Zhang
Department of Ophthalmology, The Weifang Eye Hospital, Weifang 261041, China (postgraduate student in Weifang Medical University)
Jie Zhang
Xinyan Xu
Rongyu Gao
Peng Wu
Haitao Han
Xianyong Sun
Xudong Huang
